104 research outputs found

    ํ•œ๊ตญ์ธ ์†Œ์•„ ๊ธ‰์„ฑ๋ฆผํ”„๋ชจ๊ตฌ๋ฐฑํ˜ˆ๋ณ‘์—์„œ mercaptopurine์˜ ๋…์„ฑ์— ๊ด€๋ จ๋œ ์œ ์ „์ž ๋‹คํ˜•์„ฑ ๋ถ„์„

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (๋ฐ•์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› ์˜๊ณผ๋Œ€ํ•™ ์˜ํ•™๊ณผ, 2017. 8. ์‹ ํฌ์˜.Introduction: Despite of marked improvement in survival rates of pediatric acute lymphoblastic leukemia (ALL), drug resistance and recurrence are remaining problems. Genetic polymorphism has been known to be an important factor affecting the efficacy and toxicity of antileukemic agents, thus pharmacogenetic researches have been actively conducted in pediatric ALL. Mercaptopurine (MP) is one of the main chemotherapeutics for ALL, and constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. Throughout previous studies, thiopurine methyltransferase (TPMT) is proved to be one of the most responsible genes in the pharmacogenetics of MP. Recently, mutations of nucleoside diphosphate linked moiety X-type motif 15 (NUDT15) have been shown to be a powerful genetic factor affecting the toxicity and intolerance of MP. In this study, the genetic factors affecting the toxicity of MP were investigated in Korean children with ALL. Patients and Methods: Two-stage pharmacogenetic analyses were performed to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients. A total of 185 patients with ALL who were diagnosed and treated at the Seoul National University Children's Hospital were included. First, targeted sequencing was carried out using a novel gene panel of 147 pharmacogenetics related genes and 8 SNPs in 44 patients who received less than 25% of initial dose during maintenance therapy due to MP intolerance. Next, significant genes identified in the first analysis were re-sequenced in a total of 185 patients. The relationship between mutation of each gene identified through sequencing and toxicity or dose of MP were analyzed. Results: As a result of the first stage analysis, the 4 loci which were likely to be most relevant to the toxicity of MP (NUDT15 rs116855232, APEX1 rs2307486, CYP1A1 rs4646422, BAG3 rs78439745) were identified, and 24 variants in 13 genes potentially linked to MP adverse reactions including these 4 loci were selected as final candidates for subsequent validation in a cohort of 185 patients. The distribution of variant alleles were NUDT15 rs116855232 (21.7%), APEX1 rs2307486 (13.5%), ABCC4 rs2274407 (34%), ABCC4 rs3765534 (14.1%), ABCC4 rs11568658 (23.2%), CYP4F2 rs2108622 (51.9%), CYP1A1 rs4646422 (29.1%), SLCO1B1 rs11045879 (55.7%), SLCOB1 rs4149056 (26.5%), ITPA rs1127354 (26%), ITPA rs7270101 (0%), MTHFR rs1801131 (60.5%), MTHFR rs1801133 (28.6%), MTHFR rs1901133 (50.8%), GRIA1 rs4958351 (3.8%), MOCOS rs594445 (48.1%), PACSIN2 rs2413739 (13.5%), BAG3 rs78439745 (7%) and TPMT (* 1 / * 3C, 3.8%). Neutropenia (neutrophil<500/ใŽ•) was observed in 121 patients (65.4%) during the administration of MP. When frequency of neutropenia during MP administration was crosstabulated with variant frequencies, the risk of neutropenia was 4.64 times higher in patients with T allele in ABCC4 rs3765534 (95% CI1.32 to 25.12, P=0.008). Among 121 patients with neutropenia, 15 patients had neutropenia within 30 days (early neutropenia) after starting MP, and the risk of early neutropenia was significantly higher in patients with G allele in APEX1 rs2307486 (OR=3.4495% CI1.04 to 9.89, P=0.02). In addition, the cumulative incidence of early neutropenia was significantly higher in patients with variant forms of APEX1 rs2307486 (AA:AG:GG=66.3%:73%:100%, P<0.001). The cumulative incidence of early neutropenia was also significantly increased in patients with NUDT15 rs116855232 mutations (CC:CT:TT=65.0%:72.2%:100%, P<0.001). Comparing the average doses of MP used in the study, the T allele type of NUDT15 rs116855232 was significantly associated with a lower tolerated dose of MP as 10.5, 19.4 and 28.7 mg/m2/day for TT, CT, and CC genotypes (P<0.001). However, MP doses by TPMT mutations were not significantly different in this study. Conclusion: In conclusion, this study revealed that genetic variation of APEX1 increases the risk of early neutropenia associated with MP, and the variant allele in NUDT15 was related to MP intolerance. In Korean ALL patients, toxicity and tolerance of MP were more affected by APEX1 and NUDT15 than by TPMT, which has a lower variant allele frequency in Asian. Further validation will be needed to confirm the frequency and pharmacogenetic consequences of APEX1 variants in other ethnic groups, including different Asian populationsIntroduction 1 Patients and Methods 4 Patients and treatment 4 Clinical data collection 5 Primary targeted sequencing and analysis 6 Subsequent validation with candidate gene analysis 14 Statistical analysis 20 Ethics statement 21 Results 22 Patients and treatment 22 Results of primary targeted sequencing 24 Results of subsequent candidate gene analysis 27 Neutropenia during maintenance & genotypes 30 Other toxicities during maintenance & genotypes 40 Doses of mercaptopurine, methotrexate & genotypes 43 Survival analysis & genotypes 48 Discussion 50 References 63 ๊ตญ ๋ฌธ ์ดˆ ๋ก 71Docto

    Selective inhibitory effect of epigallocatechin-3-gallate on migration of vascular smooth muscle cells

    Get PDF
    In order to prevent restenosis after angioplasty or stenting, one of the most popular targets is suppression of the abnormal growth and excess migration of vascular smooth muscle cells (VSMCs) with drugs. However, the drugs also adversely affect vascular endothelial cells (VECs), leading to the induction of late thrombosis. We have investigated the effect of epigallocatechin-3-gallate (EGCG) on the proliferation and migration of VECs and VSMCs. Both cells showed dose-dependent decrease of viability in response to EGCG while they have different IC(50) values of EGCG (VECs, 150 mM and VSMCs, 1050 mM). Incubating both cells with EGCG resulted in significant reduction in cell proliferation irrespective of cell type. The proliferation of VECs were greater affected than that of VSMCs at the same concentrations of EGCG. EGCG exerted differential migration-inhibitory activity in VECs vs. VSMCs. The migration of VECs was not attenuated by 200 mM EGCG, but that of VSMCs was significantly inhibited at the same concentration of EGCG. It is suggested that that EGCG can be effectively used as an efficient drug for vascular diseases or stents due to its selective activity, completely suppressing the proliferation and migration of VSMCs, but not adversely affecting VECs migration in blood vessels.ope

    Antimicrobial effect of medical adhesive composed of aldehyded dextran and ฮต-Poly(L-Lysine).

    Get PDF
    Infection of surgical wounds is a severe problem. Conventional tissue reattachment methods have limits of incomplete sealing and high susceptibility to infection. Medical adhesives have several advantages over traditional tissue reattachment techniques, but still have drawbacks, such as the probability of infection, low adhesive strength, and high cytotoxicity. Recently, a new medical adhesive (new-adhesive) with high adhesive strength and low cytotoxicity, composed of aldehyded dextran and ฮต-poly(L-lysine), was developed. The antimicrobial activity of the new-adhesive was assayed using agar media and porcine skin. In the agar diffusion method, inoculated microorganisms that contacted the new-adhesive were inactivated, but this was not dependent on the amount of new-adhesive. Similar to the agar media results, the topical antimicrobial effect of new-adhesive was confirmed using a porcine skin antimicrobial assay, and the effect was not due to physical blocking based on comparison with the group whose wounds were wrapped.ope

    Direct-Current Treatment as a Safe Sterilization Method for Electrospun Biodegradable Polymer

    Get PDF
    Sterilization is an essential process for biodegradable polymers to be used as biomaterials or tissue engineered- scaffolds. The characteristics of biodegradable scaffolds can change due to decomposition of constituent polymers due to high temperature, pressure, or moisture during sterilization. This study investigated directโ€“current (DC) treatment as a safe method that can prevent structural change and deformation. Treatment of electrospun poly (lactic-co-glycolic acid) (PLGA) with DC showed a bactericidal effect within 40 sec at 4 V. When DC was applied at 6 V to the electrospun PLGA, the bactericidal effect emerged within 30 sec. The morphology of fibers and molecular weight of PLGA polymer was maintained after DC treatment. In contrast, electrospun PLGA exposed to ethylene oxide showed fiber degradation, and gamma or e-beam irradiation resulted in decreased molecular weight. The demonstrated improvement in chemical and physical stability of biodegradable polymers after DC sterilization may help extend their application.ope

    Migration of Human Dermal Fibroblast is Affected by the Diameter of the Electrospun PLGA Fiber

    Get PDF
    Cell migration is an essential activity of the cells in various biological phenomena such as embryonic development, wound healing of damaged tissue, capillary vascularization in angiogenesis and migration of leukocytes to kill the bacteria around the wound site. The properties of nanofibrous surface enhancing cell adhesion, proliferation, migration and differentiation are necessary for application in tissue engineering. Recently, fabricated scaffolds at the nanometer scale are very similar to the architecture of natural human tissue, because of the development of nanofibers. In this study, we observed different cell migration behaviors on PLGA nanofibers with different diameters. 0.4 ฮผm and 1.4 ฮผm PLGA fibers were fabricated by electrospinning. Adhesion of neonatal human dermal fibroblasts (nHDFs) on the PLGA scaffolds was quantified by MTT assay. Real time observation system was used to analyze the migration of nHDF on the 0.4 ฮผm and 1.4 ฮผm PLGA scaffolds. There are no significant differences in cell attachment between 0.4 ฮผm and 1.4 ฮผm PLGA nanofibers. However, the migration was affected by the thickness of the PLGA fiber. The cells were migrated along with the 0.4 ฮผm PLGA fiber but did not cross 1.4 ฮผm PLGA fiber. In this research, it would be evaluated that different diameter of electrospun PLGA fiber effect on the cell migration and proliferation, and it could be applied for the development of the fibrous scaffold in tissue engineering.ope

    ์•„ํ† ํ”ผํ”ผ๋ถ€์—ผ ํ™˜์ž๋กœ๋ถ€ํ„ฐ ์œ ๋ž˜๋œ ์ธ๊ฐ„ํ™” ๋งˆ์šฐ์Šค ๋ชจ๋ธ ๊ตฌ์ถ• ๋ฐ ํŠน์„ฑ ๊ทœ๋ช…: ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค

    No full text
    ์•„ํ† ํ”ผํ”ผ๋ถ€์—ผ์€ ๋งŒ์„ฑ์ ์œผ๋กœ ์žฌ๋ฐœํ•˜๋Š” ์—ผ์ฆ์„ฑ ํ”ผ๋ถ€์งˆํ™˜์œผ๋กœ, ์ตœ๊ทผ 30๋…„๊ฐ„ ์ „์„ธ๊ณ„์ ์œผ๋กœ ๋ฐœ์ƒ๋ฅ ์ด ์ฆ๊ฐ€ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ ์ง€์—ญ, ์—ฐ๋ น, ์„ฑ๋ณ„, ์‚ฌํšŒ๋ฌธํ™”์  ํŠน์„ฑ์— ๋”ฐ๋ผ ๋‹ค์–‘ํ•œ ์œ ๋ณ‘๋ฅ ์„ ๋ณด์ด๋Š” heterogeneousํ•œ ์งˆ๋ณ‘์ด๋‹ค. ๋”ฐ๋ผ์„œ ํ™˜์ž ๊ฐœ๊ฐœ์ธ์—๊ฒŒ ์ ํ•ฉํ•œ ์น˜๋ฃŒ ๋ฐฉ๋ฒ•์„ ์„ ํƒํ•˜๋Š” ๊ฒƒ์ด ๋ฌด์—‡๋ณด๋‹ค ์ค‘์š”ํ•˜๋‹ค. ๋”ฐ๋ผ์„œ ์•„ํ† ํ”ผํ”ผ๋ถ€์—ผ์„ ๋ฐœ์ƒ ์›์ธ์— ๋”ฐ๋ผ ๋ณด๋‹ค ํšจ๊ณผ์ ์œผ๋กœ ์˜ˆ๋ฐฉ ๋˜๋Š” ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•œ ์—ฐ๊ตฌ๊ฐ€ ํ™œ๋ฐœํ•˜๊ฒŒ ์ด๋ฃจ์–ด์ง€๊ณ  ์žˆ๋‹ค. ์ด๋Ÿฌํ•œ ์—ฐ๊ตฌ๋ฅผ ์œ„ํ•ด ๋‹ค์–‘ํ•œ ๋งˆ์šฐ์Šค ๋ชจ๋ธ์ด ๋ณด๊ณ ๋˜๊ณ  ์žˆ๋Š”๋ฐ ๋งˆ์šฐ์Šค ๋ชจ๋ธ์—์„œ์˜ ๊ฒฐ๊ณผ๋ฅผ ์•„ํ† ํ”ผํ”ผ๋ถ€์—ผ ํ™˜์ž์—๊ฒŒ ์ ์šฉํ•˜๋Š” ๋ฐ์—๋Š” ํ•œ๊ณ„๊ฐ€ ๋ฐœ์ƒํ•œ๋‹ค. ๋”ฐ๋ผ์„œ ์•„ํ† ํ”ผํ”ผ๋ถ€์—ผ์— ๋Œ€ํ•œ ์ธ๊ฐ„ํ™” ๋งˆ์šฐ์Šค ๋ชจ๋ธ์˜ ๊ฐœ๋ฐœ์€ ๋งˆ์šฐ์Šค ๋ชจ๋ธ๊ณผ ํ™˜์ž๊ฐ„์˜ ์ฐจ์ด๋ฅผ ์ค„์ด๊ธฐ ์œ„ํ•ด ํ•„์ˆ˜์ ์ด๋ฉฐ, ์ด๋Š” ์น˜๋ฃŒ ์•ฝ๋ฌผ ๊ฐœ๋ฐœ์„ ์œ„ํ•ด ๋ณด๋‹ค ๋‚˜์€ ์ „์ž„์ƒ ๋„๊ตฌ๋กœ ์ด์–ด์งˆ ๊ฒƒ์ด๋ผ ์ƒ๊ฐ๋œ๋‹ค. ๋”ฐ๋ผ์„œ ๊ฐœ์ธ ๋งž์ถคํ˜• ์˜๋ฃŒ์˜ ์ดˆ์„์„ AD์— ์„ค์ •ํ•  ์ˆ˜ ์žˆ๋„๋ก ํ™˜์ž ๊ฐœ๊ฐœ์ธ์˜ ๋ฉด์—ญ ๋ฐ˜์‘ ํŒจํ„ด์„ ๊ตฌํ˜„ํ•˜๋Š” ์ƒˆ๋กœ์šด ๋งž์ถคํ˜• ๋งˆ์šฐ์Šค ๋ชจ๋ธ (AVATAR mouse)์„ ๊ตฌ์ถ•ํ•˜๊ณ ์ž ํ•œ๋‹ค. ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค๋Š” ์ง‘๋จผ์ง€์ง„๋“œ๊ธฐ์— ๊ฐ์ž‘ ๋œ AD ํ™˜์ž์—์„œ ์œ ๋ž˜ ํ•œ CD3 + T ์„ธํฌ์™€ CD3 depleted PBMC๋ฅผ NOD-scid IL2Rฮณnull(NSG) ๋งˆ์šฐ์Šค์— ์ด์‹ํ•˜์—ฌ ์ œ์ž‘ํ•˜์˜€๋‹ค. ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค๋ฅผ 4์ฃผ ๋™์•ˆ ์ง‘๋จผ์ง€์ง„๋“œ๊ธฐ๋ฅผ ๊ฐ์ž‘์‹œ์ผœ์ฃผ๊ณ , 4์ฃผ ํ›„ ์ง‘๋จผ์ง€์ง„๋“œ๊ธฐ๋ฅผ ๊ฐ์ž‘์‹œํ‚จ ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค์—์„œ๋Š” ์—ผ์ฆ ๋ฐ˜์‘์ด ๋ฐœ์ƒํ•˜๋Š” ๋ฐ˜๋ฉด ์ง‘๋จผ์ง€์ง„๋“œ๊ธฐ๋ฅผ ๊ฐ์ž‘์‹œํ‚ค์ง€ ์•Š์€ ๋Œ€์กฐ๊ตฐ์—์„œ๋Š” ์—ผ์ฆ ๋ฐ˜์‘์ด ๋ฐœ์ƒํ•˜์ง€ ์•Š๋Š” ๊ฒƒ์„ ๊ด€์ฐฐํ•˜์˜€๋‹ค. ๋˜ํ•œ ์ง‘๋จผ์ง€์ง„๋“œ๊ธฐ๋ฅผ ๊ฐ์ž‘์‹œํ‚จ ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค์—์„œ ํ™˜์ž์˜ CD3 + T ์„ธํฌ๊ฐ€ ๋Œ€์กฐ๊ตฐ์— ๋น„ํ•ด ์ฆ๊ฐ€ํ•˜๊ณ  4์ฃผ ํ›„์— ์ง‘๋จผ์ง€ ์ง„๋“œ๊ธฐ ํ•ญ์›์„ ์ธ์‹ํ•œ ํ™˜์ž์˜ CD1c + CD11c +HLADR +FcฮตRI + ํ•ญ์› ์ œ์‹œ ์„ธํฌ๊ฐ€ CD3 + T ์„ธํฌ๋ฅผ ํ™œ์„ฑํ™”์‹œ์ผœ ์—ผ์ฆ๋ฐ˜์‘์„ ์ผ์œผํ‚ค๋Š” ๊ฒƒ์„ ํ™•์ธํ•จ์œผ๋กœ์จ ์šฐ๋ฆฌ์˜ ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค ๋ชจ๋ธ์ด ํ•ญ์› ํŠน์ด์  T ์„ธํฌ ๋ฐ˜์‘์„ ์œ ๋ฐœํ•œ๋‹ค๋Š” ๊ฒƒ์„ ํ™•์ธํ•˜์˜€๋‹ค. ๋˜ํ•œ ๊ฐœ๊ฐœ์ธ ์•„ํ† ํ”ผํ”ผ๋ถ€์—ผ ํ™˜์ž์™€ ์ผ์น˜ํ•˜๋Š” ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค ๊ฐ„์˜ ์ž„์ƒ ์ง€ํ‘œ ์ƒ๊ด€์„ฑ์„ ํ™•์ธํ•จ์œผ๋กœ์จ ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค๊ฐ€ ์‹ค์ œ ํ™˜์ž์˜ ์งˆ๋ณ‘ ์ƒํƒœ๋ฅผ ์ž˜ ๋ฐ˜์˜ํ•ด ์ค„ ๊ฒƒ์ด๋ผ ์ƒ๊ฐ๋œ๋‹ค. ์ด๋Ÿฌํ•œ ๊ฒฐ๊ณผ๋ฅผ ํ†ตํ•ด ์•„๋ฐ”ํƒ€ ๋งˆ์šฐ์Šค๋ฅผ ํ†ตํ•ด ํ™˜์ž ๊ฐœ๊ฐœ์ธ๋ณ„ ํŠน์ด์  ๋ฉด์—ญ ๋ฐ˜์‘์„ ํ™•์ธํ•˜๊ณ  ์‹ค์ œ ์ƒˆ๋กœ ๊ฐœ๋ฐœ๋œ ์•ฝ์ œ์— ๋Œ€ํ•œ ์น˜๋ฃŒ ๋ฐ˜์‘์„ ๋ฏธ๋ฆฌ ํ™•์ธ ๋ฐ ์˜ˆ์ธกํ•  ์ˆ˜ ์žˆ๊ธฐ์— ๊ฐ€๊นŒ์šด ๋ฏธ๋ž˜์— ์•„ํ† ํ”ผํ”ผ๋ถ€์—ผ ํ™˜์ž์˜ ๊ฐœ์ธ๋งž์ถคํ˜• ์น˜๋ฃŒ ๊ฐ€๋Šฅ์„ฑ์„ ์ œ์‹œํ•˜๊ณ ์ž ํ•œ๋‹ค. Atopic dermatitis(AD) is a chronic, relapsing inflammatory skin disease with increasing incidence worldwide. AD shows a variety of immune responses with heterogeneous disease phenotypes. Thus many AD mouse models have been developed, yet the limitation occurs when the findings from mouse model is interpreted into human AD subjects. Therefore, development of humanized mouse model for AD is essential to reduce this gap between mouse model and human subjects, which will lead to more homologous pre-clinical tools for drug development in AD. By establishing the new, customized mouse model (AVATAR mouse) which represents the immune response pattern of individual AD patients, the cornerstone of personalized medicine might be set up in AD. AVATAR mouse was made by using NOD-scid IL2Rฮณnull (NSG) mouse engrafted with CD3+ T cells and peripheral blood mononuclear cells (PBMCs) derived from AD patients who were sensitized to house dust mite (HDM). The AVATAR mice were treated with HDM ointment for 4 weeks. After 4 weeks, we observed that the inflammatory response occurred in AD AVATAR mice treated with HDM ointment, whereas healthy controls (HC) AVATAR mice with HDM ointment did not. Skin engraftment of human CD3+ T cells increased gradually and maintained its number even after 4 weeks, we also confirmed the presence of human CD1c+CD11c+HLADR+FcฮตRI+ antigen presenting cells together with human CD3+ T cells, which suggests HDM-specific T-cell responses in our AVATAR mouse. Interestingly, clinical and laboratory correlation between individual AD patients and matched AVATAR mice were also observed. Taken together, our results suggest that AVATAR mouse represents the immune response of individual AD patients, which might enable the individualized, patient-oriented approach to treat AD patients in the near future.open์„

    ์ƒ๋ฆฌํ™œ์„ฑ๋ฌผ์งˆ์˜ ์ฐฝ์ƒ์น˜์œ  ์ž‘์šฉ๊ณผ ๋ณตํ•ฉ ์ง€์ง€์ฒด๋กœ์จ์˜ ์ ์šฉ

    No full text
    Dept. of Medical Science/๋ฐ•์‚ฌWound sites in skin must be immediately repaired because the skin isolates and protects from the outside. Wound sites become healing with three processes such as inflammation, proliferation and tissue remodeling. Treatment in wound sites is aiming to accelerate the wound healing, to protect the wound sites and to reduce the pain. A skin substitute, one of the treatment methods in wound sites, is used in complete section that requires epidermis and dermis. A skin substitute used commercially is made of the extracellular matrix (ECM), the living cells, the cytokines and the growth factors. However, these materials have some problems to induct the over expression of matrix metalloproteinase in wound sites and to require the cell culture times and the less validity date. In this study, we investigated the biodegradable scaffolds as a skin substitute. The scaffolds made of poly (lactic-co-glycolic acid) (PLGA) what is one of the most used biodegradable polymers was fabricated using electrospinning. Electrospinning easily fabricates the multi-fiber structure with the polymers. This structure has the advantages to provide the large surface area for cell attachment and the fluid passages. The fabricated scaffolds were investigated to composite with natural bioactive compounds instead of the cytokines and the growth factors what accelerate the wound healing. The natural bioactive compounds instead of them were used (1,3)-(1,6)-ฮฒ-D-glucans (BGs) and epigallocatechin-3-O-gallate (EGCG). BGs, a natural product of glucose polymers, have immune stimulatory activity that is especially effective in wound healing. EGCG is the major polyphenolic compound in green tea, and has been investigated to regulate the secretion of cytokines and the activation of skin cells during wound healing. First of all, the porous PLGA scaffolds were investigated by electrospinning using different process parameters. The electrospun scaffolds showed the uniformity structures when the scaffolds were fabricated with PLGA (PLA:PGA = 75:25) in HFIP or THF/DMF at 20% (w/v). These process parameters had been used for this study because the scaffolds as a skin substitute were demanded the uniformity shapes. The scaffolds processed with dry ice had a loose connection between the fibers and showed large pore sizes. The infiltration of the adult human fibroblasts was directly improved with the increase of the pore sizes of the scaffolds. Biodegradable scaffolds were sometimes deformed by heat, high temperature, pressure and moisture during sterilization. In this study, the electrospun scaffolds were treated with direct current (DC) for sterilization. During sterilization with DC treatment, the fiber structures were maintained and the microorganism sterilized with a short time. Therefore, DC treatment has the possibility of applying in the sterilization method for biodegradable scaffolds. The scaffolds composed of PLGA and BGs (BGs/PLGA scaffold) or EGCG (EGCG/PLGA scaffold) was investigated using electrospinning. The growth rate of human dermal fibroblasts (HDFs) increased in 50BGs/PLGA scaffolds (PLGA scaffolds included 50 wt% BGs) because BGs improved the HDFs proliferation. HDFs showed the cytotoxicity in PLGA scaffolds included 5 wt% EGCG (5EGCG/PLGA scaffolds) because EGCG induced caspase-3 activity to enhance that caused apoptosis. Therefore, 50BGs/PLGA scaffolds and 1EGCG/PLGA scaffolds (PLGA scaffolds included 1 wt% EGCG) were examined the wound healing effect in the animal study. According to H&E staining results, the re-epithelialization in wound sites and the cell infiltration in scaffolds were significantly accelerated the sites treated with the scaffolds included BGs or EGCG at 2 weeks after scaffold implantation. At 2 weeks, the proliferating cells (Ki-67 staining) in basal layers and the angiogenesis (CD 31 staining) in new dermis were also improved with the scaffolds included BGs or EGCG.In conclusion, BGs/PLGA scaffolds and EGCG/PLGA scaffolds should be applied as a skin substitute for accelerated wound healing. Before application to a skin substitute, the EGCG concentration in a skin substitute should be regulated because the EGCG has cytotoxicity at high concentration.ope

    ๊ณผํ•™๊ต์‚ฌ-์—ฐ๊ตฌ์ž๊ฐ„ ํ˜‘๋ ฅ์  ์›Œํฌ์ˆ์—์„œ ์‚ฌํšŒ์  ์ค‘์žฌ๋ฅผ ํ†ตํ•œ ๊ตฌ์„ฑ์ฃผ์˜ ๊ณผํ•™์ˆ˜์—…์— ๋Œ€ํ•œ ์ง‘ํ•ฉ์  ์ดํ•ด ๊ณผ์ •

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ) --์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๊ณผํ•™๊ต์œก๊ณผ(์ง€๊ตฌ๊ณผํ•™์ „๊ณต),2008.2Maste

    ํ˜„ํ™ฉ๋ถ„์„์„ ์ค‘์‹ฌ์œผ๋กœ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๋ฒ•๊ณผ๋Œ€ํ•™ ๋ฒ•ํ•™๊ณผ,2020. 2. ์†ก์„์œค.์œ„์›ํšŒ๋ž€ ๋ณต์ˆ˜์˜ ์ž์—ฐ์ธ์œผ๋กœ ๊ตฌ์„ฑ๋˜์–ด ์ง‘๋‹จ์ ์ธ ๊ฒฐ์ •์„ ๋‚ด๋ฆฌ๋Š” ํ•ฉ์˜์ œ ๊ธฐ๊ตฌ์ด๋‹ค. ์šฐ๋ฆฌ๋‚˜๋ผ๋ฅผ ํฌํ•จํ•œ ๋งŽ์€ ๊ตญ๊ฐ€๋“ค์ด ํ–‰์ •์ˆ˜์š”์˜ ๋‹ค์–‘ํ™”์™€ ํ–‰์ •๊ณผ์ •์˜ ๋ฏผ์ฃผ์„ฑ ๊ฐ•์กฐ๋กœ ๋‹จ์ž„ ๊ณ„์ธต ์กฐ์ง์—์„œ ๋ฒ—์–ด๋‚œ ์œ„์›ํšŒ ์กฐ์ง์„ ์ ๊ทน ํ™œ์šฉํ•˜๊ณ  ์žˆ๋‹ค. 2019๋…„ ํ˜„์žฌ ใ€Œํ–‰์ •๊ธฐ๊ด€ ์†Œ์† ์œ„์›ํšŒ์˜ ์„ค์น˜โ€ค์šด์˜์— ๊ด€ํ•œ ๋ฒ•๋ฅ ใ€์— ๋”ฐ๋ฅธ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ๋Š” 558๊ฐœ์ด๋‹ค. ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ๋Š” ๋น„ํšจ์œจ์„ฑ๊ณผ ์•ฝํ•œ ์ฑ…์ž„์„ฑ์ด๋ž€ ํ•œ๊ณ„๊ฐ€ ์žˆ์ง€๋งŒ, ๊ตญ๊ฐ€์™€ ์‹œ๋ฏผ์‚ฌํšŒ์˜ ๊ฒฝ๊ณ„๊ฐ€ ๋ชจํ˜ธํ•ด์ง€๊ณ  ํ–‰์ •๋ถ€ ์—ญํ• ์ด ์ปค์ง€๋Š” ์ƒํ™ฉ ์†์—์„œ ๋ฏผ๊ฐ„์˜ ์ฐธ์—ฌ๋ฅผ ๋ณด์žฅํ•˜๊ณ  ์ •์ฑ…์˜ ์ •๋‹น์„ฑ๊ณผ ์ „๋ฌธ์„ฑ์„ ์ œ๊ณ ํ•œ๋‹ค๋Š” ์žฅ์ ์ด ์žˆ๋‹ค. ๋˜ํ•œ ํ–‰์ •๋ถ€ ๋‚ด ํ•ฉ์˜์ œ ๊ธฐ๊ตฌ์˜ ์„ค์น˜๋Š” ๊ทธ ์ž์ฒด๋กœ ๊ถŒ๋ ฅ์„ ๋ถ„์‚ฐํ•˜๋Š” ํšจ๊ณผ๋„ ๊ฐ€์ ธ์˜จ๋‹ค. ์œ„์›ํšŒ์˜ ์–‘์  ํŒฝ์ฐฝ๊ณผ ํ•จ๊ป˜ ์œ„์›๊ตฌ์„ฑ๋ฐฉ์‹์—์„œ ๊ณต์ •์„ฑโ€ค๋Œ€ํ‘œ์„ฑ์„ ํ™•๋ณดํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ๊ตญํšŒ์˜ ์œ„์›์ถ”์ฒœ๊ถŒ์„ ์ธ์ •ํ•˜๋Š” ์œ„์›ํšŒ๊ฐ€ ๋Š˜์–ด๋‚˜๊ณ  ์žˆ๋‹ค. 2019๋…„ 2์›” ๊ธฐ์ค€์œผ๋กœ ๊ตญํšŒ์˜ ์œ„์›์ถ”์ฒœ๊ถŒ์„ ์ธ์ •ํ•˜๋Š” ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ๋Š” 18๊ฐœ์ด๋‹ค. ์ด ๋…ผ๋ฌธ์€ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์ธ์ •๋˜๋Š” ์ด๋“ค ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ํ˜„ํ™ฉ์„ ํŒŒ์•…ํ•˜๊ณ  ๊ทธ ์—ฐ์›๊ณผ ์‹ฌ์‚ฌ๊ณผ์ •์„ ๊ตญํšŒ ํšŒ์˜๋ก ๋ฐ ์„ ํ–‰์—ฐ๊ตฌ๋“ค์„ ํ†ตํ•ด ์กฐ์‚ฌโ€ค๋ถ„์„ํ•จ์œผ๋กœ์จ ํ˜„์‹ค์—์„œ ๊ธฐ๊ด€๊ตฌ์„ฑ ์‹œ ๋‚˜ํƒ€๋‚˜๋Š” ๊ถŒ๋ ฅ๋ถ„๋ฆฝ ๊ตฌํ˜„๋ฐฉ์‹์„ ์‚ดํŽด๋ณด๊ณ ์ž ํ•˜์˜€๋‹ค. ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ๋Š” ๊ถŒ๋ ฅ(๊ตญ๊ฐ€๊ธฐ๋Šฅ)์„ ์—ฌ๋Ÿฌ ๊ตญ๊ฐ€๊ธฐ๊ด€์— ๋ฐฐ๋ถ„ํ•˜์—ฌ ๊ทธ๋“ค ๊ฐ„์˜ ๊ฒฌ์ œ์™€ ๊ท ํ˜•์„ ํ†ตํ•˜์—ฌ ๊ถŒ๋ ฅ์„ ํ†ต์ œํ•˜๋Š” ์›๋ฆฌ์ด๋‹ค. ๊ถŒ๋ ฅ๋‚จ์šฉ์„ ๋ฐฉ์ง€ํ•˜์—ฌ ๊ตญ๋ฏผ์˜ ์ž์œ ์™€ ๊ธฐ๋ณธ๊ถŒ์„ ๋ณด์žฅํ•  ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์—ฌ๋Ÿฌ ๊ตญ๊ฐ€๊ณผ์ œ๋ฅผ ๊ฐ€์žฅ ์ ํ•ฉํ•œ ๊ธฐ๊ด€์— ๋ฐฐ๋ถ„ํ•จ์œผ๋กœ์จ ๊ตญ๊ฐ€๊ธฐ๋Šฅ์„ ํšจ์œจ์ ์œผ๋กœ ์ดํ–‰ํ•˜๋Š” ๊ฒƒ์ด ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ์˜ ํ—Œ๋ฒ•์  ๊ธฐ๋Šฅ์ด๋‹ค. ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ๋Š” ๊ณ ์ •๋ถˆ๋ณ€ํ•œ ๊ตญ๊ฐ€์กฐ์ง์›๋ฆฌ๊ฐ€ ์•„๋‹ˆ๋ผ ์‹œ๋Œ€์  ์ƒํ™ฉ์ด ๋ณ€ํ•จ์— ๋”ฐ๋ผ ๋ณ€์šฉํ•˜์˜€๋‹ค. ๊ตญ๋ฏผ์ฃผ๊ถŒ์ฃผ์˜๊ฐ€ ๋ณดํŽธํ™”๋œ ํ˜„๋Œ€์—๋Š” ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์ด ๊ถŒ๋ ฅ์ด ์•„๋‹Œ ๊ตญ๊ฐ€๊ธฐ๋Šฅ์˜ ๋ถ„๋ฆฌ๋ฅผ ์ค‘์‹ฌ์œผ๋กœ ๋…ผ์˜๋˜๋Š”๋ฐ, ์‹œ๋ฏผ์‚ฌํšŒ ๋ฐœ์ „ ๋ฐ ํ–‰์ •๊ตญ๊ฐ€ํ™”โ€ค์ •๋‹น๊ตญ๊ฐ€ํ™”์˜ ์ง„ํ–‰์œผ๋กœ ์ „ํ†ต์ ์ธ ๊ตญ๊ฐ€โ€ค์‚ฌํšŒ ํ˜น์€ ์ž…๋ฒ•โ€คํ–‰์ •โ€ค์‚ฌ๋ฒ•์˜ ๊ฒฝ๊ณ„๊ฐ€ ๋ถˆ๋ถ„๋ช…ํ•ด์ง€๊ณ  ๊ถŒ๋ ฅ๊ด€๊ณ„๊ฐ€ ๋‹ค๋ณ€ํ™”๋˜๋ฉฐ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ์ฃผ์ฒด๋‚˜ ์˜์—ญ์ด ํ™•์žฅ๋˜๊ณ  ์žˆ๋‹ค. ๊ทธ๋ ‡๋‹ค๊ณ  ๊ณ ์ „์  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ๋ก ์ด ์™„์ „ํžˆ ๋Œ€์ฒด๋œ ๊ฒƒ์€ ์•„๋‹ˆ๋‹ค. ๊ถŒ๋ ฅ์˜ ์†์„ฑ ์ƒ ๊ฒฌ์ œ์™€ ๊ท ํ˜•์„ ํ†ตํ•œ ๊ถŒ๋ ฅ์–ต์ œ์˜ ํ•„์š”์„ฑ์€ ์˜ค๋Š˜๋‚ ์—๋„ ์—ฌ์ „ํžˆ ์œ ํšจํ•˜๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค. ๊ฒฐ๊ตญ ์˜ค๋Š˜๋‚  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ๋Š” ๊ถŒ๋ ฅ์˜ ๊ท ํ˜•์„ ์ด๋ฃจ๋Š” ์š”์†Œ๋“ค์ด ๋งค์šฐ ๋ณต์žกํ•˜๊ณ  ๋‹ค์–‘ํ•ด์ง„ ์ƒํ™ฉ์„ ๋ฐ˜์˜ํ•˜๋Š” ๋™์‹œ์— ๋ฏผ์ฃผ์ฃผ์˜โ€ค๋ฒ•์น˜์ฃผ์˜ ๋“ฑ์˜ ํ—Œ๋ฒ•์งˆ์„œ ์†์—์„œ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ๋ณธ์งˆ์  ๊ฐ€์น˜๋ฅผ ํ™•๋ณดํ•˜์—ฌ์•ผ ํ•˜๋Š” ๊ณผ์ œ๋ฅผ ์•ˆ๊ณ  ์žˆ๋‹ค. ์˜ค๋Š˜๋‚  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์€ ๊ถŒ๋ ฅ์ƒํ˜ธ ๊ฐ„์˜ ๊ณตํ™”์™€ ํ˜‘๋ ฅ์„ ํฌํ•จํ•˜๊ณ  ์žˆ๊ธฐ์— ํ–‰์ •๋ถ€ ๋‚ด ๊ธฐ๊ด€์ธ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์— ์ž…๋ฒ•๋ถ€์ธ ๊ตญํšŒ๊ฐ€ ์‹ค์งˆ์ ์ธ ๊ตฌ์„ฑ๊ถŒ์„ ํ–‰์‚ฌํ•œ๋‹ค๊ณ  ํ•˜์—ฌ ๋Œ€ํ†ต๋ น์˜ ์ธ์‚ฌ ๊ถŒํ•œ์„ ์นจํ•ดํ•˜๊ณ  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ์›์น™์— ์œ„๋ฐฐ๋œ๋‹ค๊ณ  ๊ณง๋ฐ”๋กœ ๋‹จ์ •ํ•  ์ˆ˜ ์—†๋‹ค. ๋˜ํ•œ ์šฐ๋ฆฌ๋‚˜๋ผ์˜ ํ—Œ๋ฒ•์€ ๋ฏธ๊ตญ์‹์˜ ์—„๊ฒฉํ•œ ๊ถŒ๋ ฅ๋ถ„๋ฆฝํ˜•์ด ์•„๋‹ˆ๋ผ ์˜์›๋‚ด๊ฐ์ œ์  ์š”์†Œ๋ฅผ ์ผ๋ถ€ ๊ฐ€๋ฏธํ•˜๊ณ  ์žˆ๊ณ , ํ—Œ๋ฒ•๊ธฐ๊ด€์ธ ํ—Œ๋ฒ•์žฌํŒ์†Œ ์žฌํŒ๊ด€๊ณผ ์ค‘์•™์„ ๊ฑฐ๊ด€๋ฆฌ์œ„์›ํšŒ ์œ„์›์„ ์ž…๋ฒ•๋ถ€โ€คํ–‰์ •๋ถ€โ€ค์‚ฌ๋ฒ•๋ถ€๊ฐ€ ๋™์ผ๋น„์œจ๋กœ ๊ตฌ์„ฑํ•˜๊ณ  ์žˆ๋‹ค๋Š” ์ ๋„ ๊ฐ์•ˆํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค. ๋‚˜์•„๊ฐ€ ์„ธ๊ณ„ํ™”๋‚˜ ๋ณต์ง€๊ตญ๊ฐ€ ๋“ฑ์žฅ ๋“ฑ์œผ๋กœ ์ง‘ํ–‰๋ถ€ ์šฐ์œ„์ธ ํ–‰์ •๊ตญ๊ฐ€ ๊ฒฝํ–ฅ์ด ๋‘๋“œ๋Ÿฌ์ง€๋Š” ์˜ค๋Š˜๋‚ ์˜ ํ˜„์‹ค์„ ๊ฐ์•ˆํ•  ๋•Œ, ํ–‰์ •๋ถ€์— ๋Œ€ํ•œ ๊ตญํšŒ์˜ ์ ์ ˆํ•œ ์ธ์‚ฌ๊ถŒ ํ†ต์ œ๋ฅผ ๊ฐ•ํ™”ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค๋Š” ์ฃผ์žฅ๋„ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์„ ์ •๋‹นํ™”ํ•˜๋Š” ์‚ฌ์œ  ์ค‘ ํ•˜๋‚˜์ด๋‹ค. ํ•˜์ง€๋งŒ ๋ชจ๋“  ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์— ๊ตญํšŒ๊ฐ€ ์œ„์›์„ ์ถ”์ฒœํ•˜๊ฒŒ ํ•˜๋Š” ๊ฒƒ ์—ญ์‹œ ๋ฐ”๋žŒ์งํ•˜์ง€ ์•Š๋‹ค. ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ํŠน์„ฑ ์ƒ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์— ๋Œ€ํ•œ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์„ ์–ด๋””๊นŒ์ง€ ์ธ์ •ํ•  ์ˆ˜ ์žˆ๋Š”์ง€์— ๋Œ€ํ•œ ํ‘œ์ค€ํ™”๋œ ๊ธฐ์ค€์€ ์„ฑ๋ฆฝํ•˜๊ธฐ ์–ด๋ ต์ง€๋งŒ, ๊ตฌ์ฒด์ ์ธ ์‚ฌ์•ˆ์—์„œ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์ด ์ œ๋Œ€๋กœ ๊ตฌํ˜„๋˜๋Š”์ง€๋Š” ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ๋ณธ์งˆ์  ๊ธฐ๋Šฅ๊ณผ ํ—Œ๋ฒ•์  ๊ฐ€์น˜๋“ค์„ ๋น„์ถ”์–ด ์‹ค์งˆ์ ์œผ๋กœ ํŒ๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค. ์—ฌ๋Ÿฌ ๊ตญ๊ฐ€๊ณผ์ œ๋“ค์„ ์–ด๋– ํ•œ ๊ตญ๊ฐ€๊ธฐ๊ด€๋“ค์ด ์–ด๋– ํ•œ ๋ฐฉ์‹์œผ๋กœ ์ˆ˜ํ–‰ํ•  ๊ฒƒ์ธ๊ฐ€์— ๋”ฐ๋ผ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ๊ตฌ์ฒด์ ์ธ ํ˜•ํƒœ๊ฐ€ ๊ฒฐ์ •๋˜๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค. ๊ทธ๋Ÿฐ๋ฐ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์ธ์ •๋˜๋Š” ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ๋“ค์˜ ๊ฒฝ์šฐ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ ์ž์ฒด์˜ ๋ชจํ˜ธํ•จ์„ ๊ฐ์•ˆํ•˜๋”๋ผ๋„ ์ผ๊ด€์ ์ด์ง€ ์•Š์€ ๋ชจ์Šต์„ ๋ณด์˜€๋‹ค. ๊ฐœ๋ณ„์ ์ธ ๋…ผ์˜๊ณผ์ •์—์„œ ๋‹น์‹œ ์ •์น˜ ์ƒํ™ฉ์— ๋”ฐ๋ผ ์ธ์ • ์—ฌ๋ถ€๋ฅผ ํŒ๋‹จํ•˜์˜€๊ณ , ๋ฌด์—‡๋ณด๋‹ค ํ–‰์ •๋ถ€ ๋‚ด ์œ„์›ํšŒ ์ž์ฒด์— ๋Œ€ํ•œ ์ฒด๊ณ„์ ์ธ ๊ธฐ์ค€์„ ๋งˆ๋ จํ•˜๊ณ  ์žˆ์ง€ ์•Š๊ธฐ ๋•Œ๋ฌธ์ด๋‹ค. ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ ์ƒ ๊ตญ๋ฏผ์˜ ๊ธฐ๋ณธ๊ถŒ ์นจํ•ด ๊ฐ€๋Šฅ์„ฑ์ด ์ƒ๋Œ€์ ์œผ๋กœ ๋†’๊ฑฐ๋‚˜ ๋ณด๋‹ค ๋ฏผ์ฃผ์  ์ •๋‹น์„ฑ์ด ๋†’์ด ์š”๊ตฌ๋˜๋Š” ๊ฒฝ์šฐ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ ๋‚ด ๊ฒฌ์ œ์žฅ์น˜๊ฐ€ ๋”์šฑ ๊ฐ•ํ•˜๊ฒŒ ์š”๊ตฌ๋˜๋Š”๋ฐ, ์œ„์›ํšŒ์˜ ๋ฒ•์  ์œ„์ƒ์ด๋‚˜ ๊ถŒํ•œ์„ ๋‚˜ํƒ€๋‚ด๋Š” ์†Œ์† ๋ถ€์ฒ˜๋‚˜ ์‹ค์ •๋ฒ•์ƒ์˜ ํ–‰์ •์œ„์›ํšŒโ€ค์ž๋ฌธ์œ„์›ํšŒ ๊ตฌ๋ถ„์€ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ ๋„์ž… ๋…ผ์˜์—์„œ ํฌ๊ฒŒ ๊ณ ๋ ค๋˜์ง€ ์•Š์•˜๋‹ค. ์ด๋Š” ํ˜„์‹ค๊ณผ ๋ฒ• ๊ฐ„ ๊ดด๋ฆฌ๊ฐ€ ์กด์žฌํ•จ์„ ๋ฐฉ์ฆํ•œ๋‹ค. ๋‹ค๋งŒ, ํ•œ ๊ฐ€์ง€ ์œ ์˜๋ฏธํ•œ ์ ์€ ์ง€๋ฐฉ์ž์น˜โ€ง์ธ๊ถŒโ€ง๊ฐœ์ธ์ •๋ณด๋ณดํ˜ธ ๋“ฑ ํ—Œ๋ฒ•์— ๊ทœ์ •๋œ ๋ฏผ์ฃผ์ฃผ์˜์˜ ํ•ต์‹ฌ์ ์ธ ์ œ๋„ ๋‚ด์ง€ ๊ถŒ๋ฆฌ๋ฅผ ๋ณดํ˜ธโ€ง๋ณด์žฅํ•˜๊ธฐ ์œ„ํ•œ ์œ„์›ํšŒ๋‚˜ ์‚ฌํ•™๋ถ„์Ÿโ€คํ†ต์ƒ๊ต์„ญ ๋“ฑ ์ฒจ์˜ˆํ•œ ์ดํ•ด๊ด€๊ณ„ ์ถฉ๋Œ์„ ์กฐ์ •ํ•˜๊ธฐ ์œ„ํ•˜์—ฌ ๋ฏผ์ฃผ์  ์ •๋‹น์„ฑ์ด ๋งŽ์ด ์š”๊ตฌ๋˜๋Š” ์œ„์›ํšŒ๋Š” ์œ„์› ์„ ์ž„์—์„œ ๊ตญํšŒ์˜ ๊ด€์—ฌ๊ฐ€ ํ—ˆ์šฉ๋  ์—ฌ์ง€๊ฐ€ ์ƒ๋Œ€์ ์œผ๋กœ ํฌ๊ฒŒ ๋‚˜ํƒ€๋‚ฌ๋‹ค๋Š” ์ ์ด๋‹ค. ์ด๋Š” ์œ„ ์œ„์›ํšŒ๋“ค์ด ์ „ํ†ต์ ์ธ ๋ฒ•์ง‘ํ–‰๊ธฐ๋Šฅ์œผ๋กœ ๋ณด๊ธฐ ์–ด๋ ค์šด ์‚ฌ๋ฌด๋ฅผ ๋‹ด๋‹นํ•˜๊ฑฐ๋‚˜ ํ—Œ๋ฒ•์  ๊ฐ€์น˜๋ฅผ ๋ณดํ˜ธํ•˜๊ธฐ ์œ„ํ•ด ๊ถŒ๋ ฅ๋‚จ์šฉ์„ ๋ณด๋‹ค ๊ฐ•ํ•˜๊ฒŒ ๊ทœ์ œํ•˜์—ฌ์•ผ ํ•˜๋Š” ๊ฒฝ์šฐ์— ํ•ด๋‹นํ•˜๋ฏ€๋กœ, ๊ตญ๋ฏผ์˜ ๋Œ€ํ‘œ์ธ ๊ตญํšŒ์˜ ๊ฐœ์ž…์„ ๋ณด๋‹ค ๋„“๊ฒŒ ์ธ์ •ํ•˜์˜€๋‹ค๊ณ  ํ•ด์„๋œ๋‹ค. ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์„ ๋ถ€์—ฌํ•˜๋Š” ๋ฐฉ์‹๋„ ๊ตฌ์ฒด์ ์œผ๋กœ ์‚ดํŽด๋ณด์•˜๋‹ค. ์˜ค๋Š˜๋‚  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์€ ๊ธฐ๊ด€ ๊ฐ„์—๋งŒ ์ ์šฉ๋˜๋Š” ์›๋ฆฌ๊ฐ€ ์•„๋‹ˆ๋‹ค. ์‹œ๋ฏผ์‚ฌํšŒ๋‚˜ ์ •๋‹น์˜ ์ •์น˜์  ์—ญํ• ์ด ์ ์  ์ค‘์š”ํ•ด์ง€๋Š” ์ƒํ™ฉ์—์„œ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ ๊ตฌํ˜„ ์–‘์ƒ์„ ์ œ๋Œ€๋กœ ํŒŒ์•…ํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ์ด๋“ค ์—ญ์‹œ ์ค‘์š”ํ•œ ๊ณ ๋ ค์š”์†Œ์ด๋‹ค. ๊ตญํšŒ์ถ”์ฒœ๊ถŒ ํ–‰์‚ฌ์ฃผ์ฒด์™€ ๊ด€๋ จํ•˜์—ฌ ๋จผ์ €, ํ—Œ๋ฒ•๊ธฐ๊ด€์ฒ˜๋Ÿผ ์ž…๋ฒ•๋ถ€โ€คํ–‰์ •๋ถ€โ€ค์‚ฌ๋ฒ•๋ถ€๊ฐ€ ํ•จ๊ป˜ ์œ„์›์„ ๊ตฌ์„ฑํ•˜๋Š” ์œ„์›ํšŒ๋Š” ์ด 4๊ฐœ์˜€๋Š”๋ฐ 3๊ฐœ ์œ„์›ํšŒ(๊ฐœ์ธ์ •๋ณด๋ณดํ˜ธ์œ„์›ํšŒ, ๋ฏผ์ฃผํ™”๋ณด์ƒ์œ„์›ํšŒ, ์ฃผ์‹๋ฐฑ์ง€์‹ ํƒ์‹ฌ์‚ฌ์œ„์›ํšŒ)๋Š” ๋ฒ• ์ ์šฉ๋Œ€์ƒ์ด๋‚˜ ์œ„์›ํšŒ ์ง๋ฌด ๋“ฑ์„ ๊ณ ๋ คํ•œ ๊ฒฐ๊ณผ๋กœ ๋ณด์ด๋‚˜ ๋ฏผ์ฃผํ™”๋ณด์ƒ์œ„์›ํšŒ์˜ ๊ฒฝ์šฐ ๋‹ค๋ฅธ ๊ตญ๋ฌด์ด๋ฆฌ ์†Œ์† ๊ณผ๊ฑฐ์‚ฌ ๊ด€๋ จ ์œ„์›ํšŒ์™€ ๋‹ฌ๋ฆฌ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์„ ์ธ์ •ํ•œ ํŠน๋ณ„ํ•œ ์ด์œ ๋ฅผ ์ฐพ์ง€ ๋ชปํ•˜์˜€๋‹ค. ๋‚˜์•„๊ฐ€ ๊ธฐ๊ณ„์ ์œผ๋กœ 3๋ถ€์— ๊ตฌ์„ฑ ์œ„์›์ˆ˜๋ฅผ ๋™์ผ ๋น„์œจ๋กœ ๋‚˜๋ˆ„์–ด ์ถ”์ฒœํ•˜๋Š” ๋ฐฉ์‹์€ ์šฐ๋ฆฌ๋‚˜๋ผ ํ˜„์‹ค์—์„œ ์˜คํžˆ๋ ค ์œ„์›ํšŒ์˜ ์ค‘๋ฆฝ์„ฑ์„ ํ•ดํ•˜์—ฌ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ๋ฅผ ์ œํ•œํ•˜๋ฏ€๋กœ ๊ฐ€๊ธ‰์  ์ง€์–‘ํ•˜๋Š” ๊ฒƒ์ด ๋ฐ”๋žŒ์งํ•  ๊ฒƒ์ด๋‹ค. ๋‹ค์Œ, ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์„ ๊ตญํšŒ, ๊ตญํšŒ์˜์žฅ, ๊ตญํšŒ ์†Œ๊ด€ ์ƒ์ž„์œ„์›ํšŒ ์ค‘ ์–ด๋””์— ๋ถ€์—ฌํ•˜๋Š”์ง€๋ฅผ ์‚ดํŽด๋ณด์•˜๋‹ค. ๊ตญํšŒ์—์„œ ๋‹ค๋ฅธ ์ฒ˜๋ฆฌ์ ˆ์ฐจ๋ฅผ ๊ฑฐ์นจ์— ๋”ฐ๋ผ ๋ฏผ์ฃผ์  ์ •๋‹น์„ฑ์ด๋‚˜ ํšจ์œจ์  ์ž„๋ช…์˜ ์ฐจ์ด๊ฐ€ ์žˆ์„ ์ˆ˜ ์žˆ๋Š”๋ฐ ์‹ฌ์‚ฌ๊ณผ์ •์—์„œ ์ด๋Ÿฌํ•œ ์ ์ด ์ „ํ˜€ ๊ณ ๋ ค๋˜์ง€ ์•Š๊ณ  ์žˆ์—ˆ๋‹ค. ๋˜ํ•œ, ๊ต์„ญ๋‹จ์ฒด์˜ ์—ญํ• ์„ ๊ตฌ์ฒด์ ์œผ๋กœ ๋ช…์‹œํ•œ ์œ„์›ํšŒ๋Š” ์ง€์—ญ๋ฐฉ์†ก๋ฐœ์ „์œ„์›ํšŒ์™€ ๋ถํ•œ์ธ๊ถŒ์ฆ์ง„์ž๋ฌธ์œ„์›ํšŒ 2๊ฐœ์˜€๋Š”๋ฐ, ์ •๋‹น๊ตญ๊ฐ€ํ™” ํ˜„์ƒ์œผ๋กœ ์—ฌ๋‹นโ€คํ–‰์ •๋ถ€ ๋Œ€ ์•ผ๋‹น ๊ตฌ์กฐ๊ฐ€ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์—์„œ ๋”์šฑ ์ค‘์š”ํ•ด์ง€๊ณ  ์žˆ์Œ์„ ๊ฐ์•ˆํ•  ๋•Œ ๊ต์„ญ๋‹จ์ฒด์˜ ์—ญํ• ์„ ๊ตฌ์ฒด์ ์œผ๋กœ ๋ช…์‹œํ•˜๋Š” ๊ฒƒ์ด ๋ฐ”๋žŒ์งํ•œ ์ธก๋ฉด์ด ์žˆ๋‹ค. ๊ฒฐ๋ก ์ ์œผ๋กœ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ๋ณธ์งˆ์€ ๊ถŒ๋ ฅ์˜ ํ•ฉ๋ฆฌํ™”๋ฅผ ํ†ตํ•ด ๊ตญ์ •์˜ ํšจ์œจ์„ ๋†’์ด๊ณ  ๊ถ๊ทน์ ์œผ๋กœ ๊ตญ๋ฏผ์˜ ์ž์œ ์™€ ๊ถŒ๋ฆฌ๋ฅผ ๋ณด์žฅํ•˜๋Š” ๊ฒƒ์ž„์„ ๊ณ ๋ คํ•˜์—ฌ ๊ตญํšŒ์˜ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ ์œ„์›์ถ”์ฒœ๊ถŒ์ด ๋„์ž…โ€ค์šด์˜๋  ํ•„์š”๊ฐ€ ์žˆ๋‹ค. ๋‚˜์•„๊ฐ€ ๊ตญํšŒ์˜ ์ถ”์ฒœ๊ถŒ์„ ์ธ์ •ํ• ์ง€ ์—ฌ๋ถ€๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์ž„๋ช…์ฃผ์ฒด๋ฅผ ๋ˆ„๊ตฌ๋กœ ํ• ์ง€ ์—ฌ๋ถ€๋‚˜ ์กฐ๋ฌธ์„ ์–ผ๋งˆ๋‚˜ ๊ตฌ์ฒดํ™”ํ• ์ง€ ์—ฌ๋ถ€๋„ ์œ„์›ํšŒ ๊ตฌ์„ฑ์˜ ๊ณต์ •์„ฑ ๋ฐ ์ •๋‹น์„ฑ์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋ฏ€๋กœ ํ•ด๋‹น ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ์œ„์ƒ๊ณผ ๊ถŒํ•œ์„ ๊ณ ๋ คํ•˜์—ฌ ์„ธ์‹ฌํ•˜๊ฒŒ ์„ค๊ณ„ํ•  ํ•„์š”๊ฐ€ ์žˆ๋‹ค.A committee is a consensus system that consists of multiple people who make collective decisions. As social issues become more complex and people's demands for democratic governance increase, various types of committees in the government are established to coordinate various conflicts of interests by engaging many experts and citizens in the policy process. In Korea, the government committee system was activated as diverse interests emerged from the rapid changes of Korean civil society since the 1990s. According to Ministry of the Interior and Safety(2019), the number of government committees set up and operated under the current administration is 558 committees under administrative agencies. In order to fulfill its role as a consensus institution that does not remain a transit institution that justifies government policies, the fairness and objectivity of appointing committee members should be secured. This is because the substantial independence of the committee depends on how it is organized. As a result, there has been a move to enhance the fairness and representation of the committee members through the recommendation of the National Assembly, the people's representative. Many cases have been legislated to recognize the right to recommend the National Assembly to the government committee, and a lot of bills have been proposed in the 20th National Assembly. Today, the principle of separation of powers has been transformed into a functional separation of power encompassing republics and cooperation among the parties of power, not a break between the legislative, administrative and judicial branches. Therefore, it cannot be concluded that the legislature violates that principle of separation of powers just by appointing the members of the government committee. Rather, it could have the effect of enhancing the legitimacy of the committee. The Constitutional Court also ruled that the current law which allows the National Assembly, the President, and Chief of Supreme Court to have the right to organize a Private School Dispute Mediation Committee under the Ministry of Education, is fair and constitutional. Moreover, as the administration is gradually strengthening its power due to rising welfare demand, there is growing need for the legislative branch to control the executive branch properly. However, it is questionable whether the National Assembly will recognize the right to recommend committees members without limit. Lawmakers legislative right to form legislation is not limitless. Article 66 Clause 4 of the Constitution stipulates that administrative power belongs to the government headed by the president, and Article 78 specifies the president's right to appoint civil servants. If the National Assembly excessively restricts administrative power beyond the scope of checks and balances, this is not only unconstitutional but could also cause many conflicts in the course of actual operation. Also, because the essence of separation of power is to guarantee the freedom and human rights through rationalization of power, it is not desirable to make National Assembly have the right to appoint members that in turn, will lower the committees expertise and efficiency. After all, it is an important constitutional task to check the president's arbitrary abuse of personnel rights while ensuring the responsibility and efficiency of state affairs without infringing on his right to appoint officials by other state agencies. As for the traditional administrative organization such as the prime minister or the ministries, the scope and method of control of the National Assembly are somewhat institutionalized under related statutes like the Constitution, the National Assembly Act, and the Personnel Management Act. However, the committee-type administrative organization, which has been widely used in modern society due to the diversification of administrative needs and the emphasis on democracy in the administrative process, has not been dealt with sufficiently. The purpose of this paper is to compile and to analyze the current status of the Government Committee's recommendation authority to the National Assembly to find a reasonable distribution of power between the legislature and the administration. The administrative bodies committee with the right to recommend the National Assembly was 18 out of a total of 558. It was difficult to find common features among them because setting the recommendation right depended on the individual political situation at that time without any specific criteria. Whether it is administrative or advisory committees, which are criteria under the Act, was not a significant standard. Also, both the scope of authority and organizational structure of the Committee were not important factor. I just illustrated that it is highly likely that the National Assembly will be allowed to participate in the selection of members of the committees which deals with policy areas of great concern to the people of the time or committees that require a lot of democratic legitimacy. In conclusion, the issue of allowing the government committee to intervene in the National Assembly's personnel affairs was largely decided as a result of political compromise or referring to previous cases without much thought. The government system needs to be designed and operated in such a way as to effectively guarantee the people's freedom and rights through rationalization of power. Therefore, it is necessary to carefully design whether or not the National Assembly will make the right to recommend members of government committee, taking into account the committee's status and authority.์ œ 1 ์žฅ ์„œ๋ก  1 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ์˜ ๋ฐฐ๊ฒฝ๊ณผ ๋ชฉ์  1 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ์˜ ๋ฒ”์œ„์™€ ๋ฐฉ๋ฒ• 3 ์ œ 2 ์žฅ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ํ™•๋Œ€์™€ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ๋ก ์˜ ์ „๊ฐœ 7 ์ œ 1 ์ ˆ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ์›๋ฆฌ์™€ ๊ธฐ๋Šฅ 7 ์ œ 2 ์ ˆ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ๋ก ์˜ ์—ญ์‚ฌ์  ์ „๊ฐœ 9 โ… . ๊ณ ์ „์  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ๋ก  9 1. ๋กœํฌ(J. Locke) 9 2. ๋ชฝํ…Œ์Šคํ‚ค์™ธ(Montesquieu) 10 3. ๋ฏธ๊ตญ ๊ฑด๊ตญ์˜ ์•„๋ฒ„์ง€๋“ค(Founding Fathers) 12 4. ๊ณ ์ „์  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ๋ก ์˜ ํŠน์ง• 14 โ…ก. 20์„ธ๊ธฐ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ๋ก ์˜ ๋ณ€์šฉ 15 1. ์บ๊ธฐ(W. Kรคgi) 15 2. ๋ขฐ๋ฒค์Šˆํƒ€์ธ(K. Loewenstein) 16 3. ์Šˆํ…Œ๋ฅธ(K. Stern) 17 4. ๊ธฐ๋Šฅ์  ๊ถŒ๋ ฅ๋ถ„๋ฆฝ๋ก ์˜ ํŠน์ง• 18 ์ œ 3 ์ ˆ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ์— ๊ด€ํ•œ ํ—Œ๋ฒ•ํ•ด์„๋…ผ์Ÿ 20 โ… . ๋ฌธ์ œ์˜ ์†Œ์žฌ: ๊ถŒ๋ ฅ๋ถ„๋ฆฝ ๊ฐœ๋…์˜ ๋ชจํ˜ธ์„ฑ 20 โ…ก. ๋ฏธ๊ตญ ์—ฐ๋ฐฉ๋Œ€๋ฒ•์›์˜ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ ํ•ด์„๋ก  20 โ…ข. ๊ถŒ๋ ฅ๋ถ„๋ฆฝํ•ด์„๋ก ์— ๋Œ€ํ•œ ํ‰๊ฐ€ 23 ์ œ 4 ์ ˆ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์™€ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ํ˜„๋Œ€์  ์˜๋ฏธ 24 โ… . ์„œ์„ค 24 โ…ก. ์ƒˆ๋กœ์šด ํ–‰์ •์กฐ์ง์ธ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ 25 1. ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ๊ฐœ๋… 25 2. ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ๋ถ„๋ฅ˜ 27 3. ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ํ•„์š”์„ฑ ๋ฐ ํ•œ๊ณ„ 29 โ…ข. ๊ตญ๊ฐ€๊ถŒ๋ ฅ์„ ๋‘˜๋Ÿฌ์‹ผ ์‹œ๋Œ€์  ๋ณ€ํ™”์™€ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ 30 1. ์‹œ๋ฏผ์‚ฌํšŒ์˜ ๋ฐœ์ „ 30 2. ํ–‰์ •๊ตญ๊ฐ€ ํ˜„์ƒ 31 3. ์ •๋‹น์˜ ์˜ํ–ฅ๋ ฅ ํ™•๋Œ€ 32 โ…ฃ. ์ƒˆ๋กœ์šด ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์˜ ํŠน์ง• 33 1. ๋‹ค์–‘ํ•œ ๊ถŒ๋ ฅ๋ณด์œ ์ฃผ์ฒด ๋“ฑ์žฅ 33 2. ๋‹ค์ธต์  ์˜์—ญ์œผ๋กœ์˜ ํ™•์žฅ 35 3. ์ „ํ†ต์ ์ธ ๊ถŒ๋ ฅ๋ถ„๋ฆฝ์›๋ฆฌ์˜ ์กด์† 36 ์ œ 5 ์ ˆ ์†Œ๊ฒฐ 37 ์ œ 3 ์žฅ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์— ๋Œ€ํ•œ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ ๋„์ž… ํ˜„ํ™ฉ 40 ์ œ 1 ์ ˆ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ ์„ค์น˜ ํ˜„ํ™ฉ 40 ์ œ 2 ์ ˆ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์ธ์ •๋˜๋Š” ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ ํ˜„ํ™ฉ 42 โ… . ๊ฐœ๊ด€ 42 โ…ก. ์œ„์›ํšŒ๋ณ„ ๊ฒ€ํ†  44 1. ์˜์•ˆ๋‹จ๊ณ„๋ถ€ํ„ฐ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์ธ์ •๋œ ๊ฒฝ์šฐ 44 2. ๊ตญํšŒ์‹ฌ์‚ฌ๊ณผ์ •์— ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์ถ”๊ฐ€๋œ ๊ฒฝ์šฐ 59 3. ๊ตญํšŒ์—์„œ ์‹ค์งˆ์  ์‹ฌ์‚ฌ ์—†์ด ์ •์น˜์  ํƒ€ํ˜‘์˜ ๊ฒฐ๊ณผ๋กœ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์‹ ์„ค๋œ ๊ฒฝ์šฐ 67 ์ œ 3 ์ ˆ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ๋„์ž… ๋…ผ์˜ ์ค‘์ธ ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ ํ˜„ํ™ฉ 74 โ… . ๊ฐœ๊ด€ 74 โ…ก. ์˜์•ˆ๋ณ„ ๊ฒ€ํ†  75 1. 3๋ถ€(้ƒจ)๊ฐ€ ์œ„์›ํšŒ ๊ตฌ์„ฑ๊ถŒ์„ ํ–‰์‚ฌํ•˜๋ ค๋Š” ์˜์•ˆ 75 2. ๊ตญํšŒ์˜ ์ถ”์ฒœ๊ถŒ์„ ์‹ ์„คํ•˜๋ ค๋Š” ์˜์•ˆ 76 ์ œ 4 ์ ˆ ์†Œ๊ฒฐ 80 ์ œ 4 ์žฅ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์ธ์ •๋˜๋Š” ํ–‰์ •๊ธฐ๊ด€์œ„์›ํšŒ์˜ ๋ถ„์„ 82 ์ œ 1 ์ ˆ ์„œ์„ค 82 ์ œ 2 ์ ˆ ํ—Œ๋ฒ•์งˆ์„œ์™€ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ ์ œ๋„ 84 ์ œ 3 ์ ˆ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ์ด ์ธ์ •๋œ ์œ„์›ํšŒ์˜ ์ง€์œ„์™€ ๊ถŒํ•œ 87 โ… . ์œ„์›ํšŒ์˜ ๋ฒ•์  ์ง€์œ„ ๋ฐ ๊ถŒํ•œ ๊ฒ€ํ† ์˜ ํ•„์š”์„ฑ 87 โ…ก. ๋ฒ•์  ๊ทผ๊ฑฐ ๋ฐ ์†Œ์†๊ธฐ๊ด€ 88 1. ์œ„์›ํšŒ ์„ค์น˜๊ทผ๊ฑฐ 88 2. ์œ„์›ํšŒ ์†Œ์†๊ธฐ๊ด€ 89 โ…ข. ํ–‰์ •์œ„์›ํšŒโ€ค์ž๋ฌธ์œ„์›ํšŒ ๊ตฌ๋ถ„ 91 โ…ฃ. ์œ„์›ํšŒ ๋ฒ•์  ๊ถŒํ•œ 92 โ…ค. ์œ„์›ํšŒ ์—…๋ฌด๋ถ„์•ผ 95 โ…ฅ. ๋ฏผ๊ฐ„์œ„์›ํšŒ ์—ฌ๋ถ€ 97 ์ œ 4 ์ ˆ ๊ตญํšŒ์ถ”์ฒœ๊ถŒ ๋ถ€์—ฌ์˜ ๋ฐฉ์‹ 98 โ… . ์ถ”์ฒœ๊ถŒ ํ–‰์‚ฌ์ฃผ์ฒด 98 1. 3๋ถ€(้ƒจ)๊ฐ€ ํ•จ๊ป˜ ์œ„์›์„ ๊ตฌ์„ฑํ•˜๋Š”์ง€ ์—ฌ๋ถ€ 98 2. ๊ตญํšŒ ๋‚ด ์ถ”์ฒœ์ฃผ์ฒด์˜ ์ฐจ์ด 99 3. ์‹œ๋ฏผ๋‹จ์ฒด ๋“ฑ ๋‹ค๋ฅธ ๊ธฐ๊ด€โ€ค๋‹จ์ฒด์˜ ์ถ”์ฒœ๊ถŒ ์ธ์ • ์—ฌ๋ถ€ 100 โ…ก. ๊ต์„ญ๋‹จ์ฒด์˜ ์—ญํ•  ๋ช…์‹œ ์—ฌ๋ถ€ 101 โ…ข. ๊ทธ ๋ฐ–์˜ ์กฐ๋ฌธ์˜ ๊ตฌ์ฒดํ™” ์ •๋„ 104 1. ๊ตญํšŒ์ถ”์ฒœ ์ธ์›์ˆ˜ 104 2. ์ž๊ฒฉ์š”๊ฑด 104 3. ์‚ฌ๋ฌด๊ตญ ๋“ฑ ์ง€์›์กฐ์ง 105 ์ œ 5 ์ ˆ ์†Œ๊ฒฐ 106 ์ œ 5 ์žฅ ์ •๋ฆฌ ๋ฐ ๊ฒฐ๋ก  108 ์ฐธ๊ณ ๋ฌธํ—Œ 114 Abstract 119Maste

    Framework of technology patent monitoring on strategic standpoint and development of technology patent map

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :์‚ฐ์—…๊ณตํ•™๊ณผ,2005.Maste
    • โ€ฆ
    corecore